Evidence map›Paper›PMID 38512301›Full record

SynthesisJAMA oncology2024

Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.

Mark Sorin, Connor Prosty, Louis Ghaleb, Kathy Nie, Khaled Katergi, Muhammad H Shahzad, Laurie-Rose Dubé, Aline Atallah, Anikka Swaby, Matthew Dankner and 8 more

4 registry-linked trialsOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in JAMA oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 129 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 17 pooled it
49.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07528066 recruitingnot on this mapstarted 2026, after this paper: background citation

The Impact of Downstaging on Robotic Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer

TypeobservationalSponsorShanghai Chest HospitalRan2026 to 2027Enrolled200ConditionsNeoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLCArmsRobotic-assisted surgery (RATS)
NCT07559123 recruitingnot on this mapstarted 2026, after this paper: background citation

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

Typeobservational_patient_registrySponsorSamsung Medical CenterRan2026 to 2028Enrolled150ConditionsNSCLC, Neoadjuvant Chemoimmunotherapy, CTArmsHigh-resolution deep learning-based CT reconstruction
NCT07561983 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)

TypeinterventionalSponsorSichuan Cancer Hospital and Research InstituteRan2026 to 2028Enrolled39ConditionsUnresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, TherapeuticArmsTislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE)
NCT07754812 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter, Open-Label, Single-Arm Phase I/II Study of Oral Paclitaxel Solution Combined With an Immune Checkpoint Inhibitor and Concurrent Stereotactic Body Radiotherapy as Neoadjuvant Treatment in Older Patients With Resectable Stage IIA-IIIB Non-Small Cell Lung Cancer

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2026 to 2028Enrolled78ConditionsNSCLC (Non-small Cell Lung Cancer)ArmsOral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT), Radical Lung Cancer Surgery
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 17 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Valid surrogate end-points in nonsmall cell lung cancer peri-operative systemic therapy trials: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
    Trial
  20. Trial

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Mark SorinRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Connor ProstyFaculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Louis GhalebFaculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Kathy NieFaculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Khaled KatergiFaculty of Medicine, University of Montreal, Montréal, Quebec, Canada.
Muhammad H ShahzadFaculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Laurie-Rose DubéFaculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Aline AtallahRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Anikka SwabyRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Matthew DanknerRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Trafford CrumpDepartment of Surgery, McGill University, Montréal, Quebec, Canada.
Logan A WalshRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
Pierre O FisetDepartment of Pathology, McGill University, Montréal, Quebec, Canada.
Boris SepesiDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick M FordeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland.
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Mariano ProvencioDepartment of Medical Oncology, Puerta de Hierro University Hospital, Autonomous University, Madrid, Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia de Arana, Spain.
Jonathan D SpicerRosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
McGill University · CAMcGill University Health Centre · CAThe University of Texas MD Anderson Cancer Center · USBloomberg (United States) · USHospital Universitario Puerta de Hierro Majadahonda · ESUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: To date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non-small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there exists controversy concerning the efficacy of neoadjuvant chemoimmunotherapy for patients with NSCLC with programmed cell death 1 ligand 1 (PD-L1) levels less than 1%. Objective: To compare neoadjuvant chemoimmunotherapy with chemotherapy by adverse events and surgical, pathological, and efficacy outcomes using recently published randomized clinical trials and nonrandomized trials. Data Sources: MEDLINE and Embase were systematically searched from January 1, 2013, to October 25, 2023, for all clinical trials of neoadjuvant chemoimmunotherapy and chemotherapy that included at least 10 patients. Study Selection: Observational studies and trials reporting the use of neoadjuvant radiotherapy, including chemoradiotherapy, molecular targeted therapy, or immunotherapy monotherapy, were excluded. Main Outcomes and Measures: Surgical, pathological, and efficacy end points and adverse events were pooled using a random-effects meta-analysis. Results: Among 43 eligible trials comprising 5431 patients (4020 males [74.0%]; median age range, 55-70 years), there were 8 randomized clinical trials with 3387 patients. For randomized clinical trials, pooled overall survival (hazard ratio, 0.65; 95% CI, 0.54-0.79; I2 = 0%), event-free survival (hazard ratio, 0.59; 95% CI, 0.52-0.67; I2 = 14.9%), major pathological response (risk ratio, 3.42; 95% CI, 2.83-4.15; I2 = 31.2%), and complete pathological response (risk ratio, 5.52; 95% CI, 4.25-7.15; I2 = 27.4%) favored neoadjuvant chemoimmunotherapy over neoadjuvant chemotherapy. For patients with baseline tumor PD-L1 levels less than 1%, there was a significant benefit in event-free survival for neoadjuvant chemoimmunotherapy compared with chemotherapy (hazard ratio, 0.74; 95% CI, 0.62-0.89; I2 = 0%). Conclusion and Relevance: This study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. These findings suggest that patients with resectable NSCLC with tumor PD-L1 levels less than 1% may have an event-free survival benefit with neoadjuvant chemoimmunotherapy.

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsNeoadjuvant TherapyAgedHumansMiddle AgedTreatment Outcome

Identifiers

PMID38512301
PMCPMC10958389
OpenAlexW4393037627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.